EPA Removes Part of Libby Asbestos Cleanup from Superfund List

The U.S. Environmental Protection Agency has deleted a 45-acre portion of the Libby Asbestos Superfund site from the National Priorities List. The EPA and the Montana Department of Environmental Quality have agreed that institutional controls to prevent any future exposure to asbestos in the area were satisfied. It’s a step closer to finishing the decontamination of the longest-running, man-made environmental disaster in American history. The sprawling Superfund site, which was placed on the National Priorities List in 2002, was originally divided into eight operable units. The units were based upon the extent of contamination and complexity of cleanup needed. Operable Unit 2 last week was the first of the eight removed. All but one other operable unit — the actual mine site — are expected to follow soon. “This is a huge step,” Mike Cirian, EPA remedial project manager, told The Mesothelioma Center at Asbestos.com. “To see this now, to know we’ve made this a safer place to live, a place I’m happy to have my grandkids come, is big.” Vermiculite Mining for 70 Years The Superfund site was created because of high levels of amphibole asbestos throughout the communities of Libby and nearby Troy, in northwest Montana. The contamination stemmed from the massive W.R. Grace &Company vermiculite mine operation that once spread asbestos dust throughout the region, sickening miners and nearby residents who never worked there. The ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

The U.S. Food &Drug Administration on Thursday approved Tumor Treating Fields, a therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth, for the first-line treatment of malignant pleural mesothelioma. It is the first treatment in more than 15 years that the FDA approves for mesothelioma. In 2004, the agency added the chemotherapy drug pemetrexed (Alimta) to standard-of-care treatment. The FDA approved Novocure’s NovoTTF-100L System under the agency’s Humanitarian Device Exemption. The approval comes eight months after Novocure, which manufactures and markets the devi...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Sarah Cannon Research Institute in Nashville, Tennessee, and MD Anderson Cancer Center in Houston have opened a much-anticipated clinical trial involving a novel T-cell therapy for patients with mesothelioma. The two institutions are establishing dosage levels and measuring efficacy of TC-210, a type of immunotherapy that targets mesothelin, a cell surface protein highly expressed in several cancers. The study also is open to patients with certain types of bile duct, ovarian and non-small cell lung cancer. Participation is based upon individual levels of mesothelin expression. Researchers at the two centers are hoping to ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More than a dozen senior officials and experts at the Environmental Protection Agency urged the EPA to ban asbestos outright, a new report shows. Two internal memos obtained by the Asbestos Disease Awareness Organization and shared with the New York Times reveal the EPA’s own scientists and lawyers advised the agency to issue a complete ban of asbestos instead of the recent regulations that only restricted its domestic use. In the memos, dated Aug. 10, 2018, EPA staff members wrote that the agency “should seek to ban all new uses of asbestos because the extreme harm from this chemical substance outweighs any ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSIONS: These promising preclinical results supported the transition of BAY 2287411 into a clinical phase I program in mesothelioma and ovarian cancer patients (NCT03507452). PMID: 31064781 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
This study evaluated the oxidative stress in chronic lung toxicity caused by the intratracheal instillation (IT) of four kinds China representative chrysotile once a month for 12 months in Wistar rats. These results indicated that chrysotile exposure led to an obvious increase in lung mass and slowed the growth of body mass. Inflammation and fibrosis were observed by hematoxylin-eosin (HE) staining. Exposure to chrysotile significantly increased the accumulation of reactive oxygen species (ROS) and the level of lipid peroxidation and decreased antioxidant capacity in lung tissues. Furthermore, 1-6-month chrysotile exp...
Source: Environmental Science and Pollution Research International - Category: Environmental Health Authors: Tags: Environ Sci Pollut Res Int Source Type: research
This study is an important step forward in highlighting C1q as a new prognostic candidate biomarker for a range of carcinomas. Methods Oncomine Database Analysis The expression levels of C1QA, C1QB, and C1QC genes in various carcinomas were analyzed using Oncomine (www.oncomine.org), a cancer microarray database and web-based data mining platform from genome-wide expression analyses (22, 23). We compared the differences in mRNA level between normal tissue and carcinoma. The mRNA expression levels in neoplastic tissues compared to the healthy tissues were obtained as the parameters of p-value 2, and gene ranking in the t...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions: We found different patterns in mortality in the main asbestos-related tumors.
Source: Journal of Occupational and Environmental Medicine - Category: Occupational Health Tags: ORIGINAL ARTICLES Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study hypothesized that similar VOCs might be detected after HBOT. Methods: Ten healthy volunteers of the Royal Netherlands Navy underwent six HBOT sessions (95 min at 253 kPa, including three 5-min “air breaks”), i.e., on five consecutive days followed by another session after 2 days of rest. At 30 min before the dive, and at 30 min, 2 and 4 h post-dive, exhaled breath was collected and followed by PFT. Exhaled breath samples were analyzed using gas chromatography-mass spectrometry (GC-MS). After univariate tests and correlation of retention times, ion fragments could be identified using a reference data...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Conditions:   Advanced and/or Metastatic Solid Tumors;   Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer;   Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma Interventions:   Drug: INCMGA00012;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel Sponsor:   Incyte Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asbestosis | Cancer | Cancer & Oncology | Economy | Environmental Health | Jobs | Lung Cancer | Mesothelioma | Tax | Toxicology